Anticoagulant therapy in case of atrial fibrillation for patients with chronic kidney disease


DOI: https://dx.doi.org/10.18565/therapy.2020.3.84-92

Poteshkina N.G., Krylova N.S., Mikheeva L.V., Khadzegova A.B.

N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow
The review deals with the aspects concerning kidney damage prevalence in case of atrial fibrillation (AF), also it contains the points concerning difficulties in choosing anticoagulant therapy, taking into account the stage of chronic kidney disease (CKD). Review of the literature on the comparative efficacy and safety of major direct oral anticoagulants and warfarin for various stages of CKD is given, and the positions of various societies for the prevention of thromboembolic complications in AF are compared. The choice of the optimal anticoagulant with individual adjustment of an effective and safe dose that can reduce the risk of thromboembolic complications without the development of bleeding is discussed.
Keywords: edoxaban, direct oral anticoagulants, rivaroxaban, dabigatran, chronic kidney disease, warfarin, atrial fibrillation
Read entire article

Literature


  1. Колбин А.С., Мосикян А.А., Татарский Б.А. Социально-экономическое бремя фибрилляции предсердий в России: динамика за 7 лет (2010–2017 годы). Вестник аритмологии. 2018; 92: 42–49. [Kolbin A.S., Mosikyan A.A., Tatarsky B.A. Socioeconomic burden of atrial fibrillations in Russia: seven-year trends (2010-2017). Vestnik aritmologii. 2018; 92: 42–49 (In Russ.)].

  2. Zoni-Berisso M., Lercari F., Carazza T. et al. Epidemiology of atrial fibrillation: European perspective. Clin Epidemiol. 2014; 6: 213–20. doi: 10.2147/CLEP.S47385.

  3. Hart R.G., Pearce L.A., Asinger R.W., Herzog C.A. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011; 6(11): 2599–604. doi:10.2215/CJN.02400311.

  4. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease International Supplements Volume 3 Issue 1 January 2013. doi:10.1038/kisup.2012.48

  5. Avezum A., Lopes R.D., Schulte P.J. et al. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015; 132(8): 624–32. doi: 10.1161/CIRCULATIONAHA.114.014807.

  6. Kumar S., de Lusignan S., McGovern A. et al. Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care. BMJ. 2018; 360: k342. doi: 10.1136/bmj.k342.

  7. Dahal K., Kunwar S., Rijal J. et al. Stroke, major bleeding, and mortality outcomes in warfarin users with atrial fibrillation and chronic kidney disease: a meta-analysis of observational studies. Chest. 2016; 149(4): 951–99. doi: 10.1378/chest.15-1719.

  8. Services USDoHaH. XARELTO (RIVAROXABAN) Safetyrelated labeling changes approved by FDA Center for Drug Evaluation and Research (CDER). In: Services USDoHaH, editor.: U.S. Department of Health and Human Services; 2016.

  9. Watanabe H., Watanabe T., Sasaki S. et al. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. Am Heart J. 2009; 158(4): 629–36. doi: 10.1016/j.ahj.2009.06.031.

  10. Shah M., Avgil Tsadok M., Jackevicius C.A. et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation. 2014; 129(11):1196–203. doi: 10.1161/CIRCULATIONAHA.113.004777.

  11. Yao X., Tangri N., Gersh B.J. et al. Renal outcomes in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2017; 70(21): 2621–32. doi: 10.1016/j.jacc.2017.09.1087.

  12. Землянская О.А., Кропачева Е.С., Добровольский А.Б., Панченко Е.П. Функция почек у больных, длительно принимающих варфарин (5-летнее проспективное наблюдение). Терапевтический архив. 2017; 89(9): 78–86. [Zemlyanskaya O.A., Kropacheva E.S., Dobrovolsky A.B., Panchenko E.P. Renal function in patients receiving long-term warfarin therapy: A five-year prospective follow-up. Terapevticheskiy arkhiv. 2017; 89(9): 78–86 (In Russ.)]. doi.org/10.17116/terarkh201789978-86.

  13. January C.T., Wann L.S., Alpert J.S. et al. AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation circulation. 2014; 130: e199–e267 doi.org/10.1161/CIR.0000000000000041.

  14. Tsai C., Marcus L.Q., Patel P. et al. Warfarin use in hemodialysis patients with atrial fibrillation: a systematic review of stroke and bleeding outcomes. Can J Kidney Health Dis. 2017; 4: 2054358117735532. doi:10.1177/2054358117735532.

  15. Bohm M., Ezekowitz M.D., Connolly S.J. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol. 2015; 65(23): 2481–93. doi: 10.1016/j.jacc.2015.03.577.

  16. Li Y.G., Miyazawa K., Wolff A. et al. One-year risks of stroke and mortality in patients with atrial fibrillation from different clinical settings: The Gulf SAFE registry and Darlington AF registry. Int J Cardiol. 2019; 274:158–62. doi: 10.1016/j.ijcard.2018.08.091.

  17. Даабуль И.С., Соколова А.А., Напалков Д.А. Возможности современной антикоагулянтной терапии у пациентов с неклапанной этиологией фибрилляции предсердий и хронической болезнью почек. Рациональная фармакотерапия в кардиологии. 2016; 12(5): 595–602. [Daabul I.S., Sokolova A.A., Napalkov D.A. Features of modern anticoagulant therapy in patients with nonvalvular atrial fibrillation and chronic kidney disease. Ratsional'naya farmakoterapiya v kardiologii. 2016; 12(5): 595–602 (In Russ.)]. https://doi.org/10.20996/1819-6446-2016-12-5-595-602.

  18. Yoon C.Y., Noh J., Jhee J.H. et al. Warfarin use in patients with atrial fibrillation undergoing hemodialysis: a nationwide population-based study. Stroke. 2017; 48(9): 2472–79. doi: 10.1161/STROKEAHA.117.017114.

  19. Spencer R.J., Amerena J.V. Rivaroxaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: clinical implications of the ROCKET AF trial and its subanalyses. American Journal of Cardiovascular Drugs. 2015; 15(6), 395–401. doi: 10.1007/s40256-015-0127-2.

  20. Avezum A., Oliveira G.B.F., Diaz R. et al. Efficacy and safety of dabigatran versus warfarin from the RE-LY trial Open Heart. 2018 Jun 27; 5(1): e000800. doi: 10.1136/openhrt-2018-000800.

  21. Vinereanu D., Lopes R.D., Mulder H. et al. Echocardiographic risk factors for stroke and outcomes in patients with atrial fibrillation anticoagulated with apixaban or warfarin. Stroke. 2017; 48(12): 3266–73. doi: 10.1161/STROKEAHA.117.017574.

  22. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016; 50(5): e1–e88.

  23. Sparkenbaugh E.M., Chantrathammachart P., Mickelson J. et al. Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease. Blood. 2014; 123(11): 1747–56. doi: 10.1182/blood-2013-08-523936.

  24. Kalz J., ten Cate H., Spronk H.M. Thrombin generation and atherosclerosis. J Thromb Thrombolysis. 2014; 37(1): 45–55. doi: 10.1007/s11239-013-1026-5.

  25. Kirchhof P., Radaideh G., Kim Y.H. et al. Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme (realworld, prospective, observational studies for stroke prevention in patients with atrial fibrillation). Eur Heart J. 2017; 38(Suppl.): 768–69.

  26. Heidbuchel H., Verhamme P., Alings M. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17(10): 1467–507. doi: 10.1093/europace/euv309.

  27. Steffel J., Verhamme P., Potpara T.S. et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16): 1330–93. doi: 10.1093/eurheartj/ehy136.

  28. Lip G.Y., Haguenoer K., Saint-Etienne C. et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014; 146(3): 719–26. doi: 10.1378/chest.13-2976.

  29. Gallego P., Roldan V., Marin F. et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014; 127(11): 1083–88. doi: 10.1016/j.amjmed.2014.05.023.

  30. Tan J., Liu S., Segal J.B. et al. Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis. BMC Nephrol. 2016; 17(1): 157. doi:10.1186/s12882-016-0368-6.

  31. Cohen A.T., Hill N.R., Luo X. et al. A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: A comparison of efficacy and safety following treatment with direct oral anticoagulants. Int J Cardiol. 2018; 269:174–81. doi: 10.1016/j.ijcard.2018.06.114.

  32. O’Brien E.C., Simon D.N., Thomas L.E. et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. Eur Heart J. 2015; 36(46): 3258–64. doi: 10.1093/eurheartj/ehv476.

  33. Graham D.J., Reichman M.E., Wernecke M. et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 176(11): 1662–71. doi:10.1001/jamainternmed.2016.5954.

  34. Sherwood M.W., Nessel C.C., Hellkamp A.S. et al. Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF Trial. J Am Coll Cardiol. 2015; 66(21): 2271–81. doi: 10.1016/j.jacc.2015.09.024.

  35. Bonde A.N., Lip G.Y., Kamper A.L. et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. J Am Coll Cardiol. 2014; 64(23): 2471–82. doi: 10.1016/j.jacc.2014.09.051.

  36. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. European Medicines Agency, 2016.

  37. Olesen J.B., Lip G.Y., Kamper A.L. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med. 2012; 367(7): 625–35. doi: 10.1056/NEJMoa1105594.

  38. Carrero J.J., Evans M., Szummer K. et al. Warfarin, kidney dysfunction, and outcomes following acute myocardial infarction in patients with atrial fibrillation. JAMA. 2014; 311(9): 919–28. doi: 10.1001/jama.2014.1334.

  39. 3Shen J.I., Montez-Rath M.E., Lenihan C.R. et al. Outcomes after warfarin initiation in a cohort of hemodialysis patients with newly diagnosed atrial fibrillation. Am J Kidney Dis. 2015; 66(4): 677–88. doi: 10.1053/j.ajkd.2015.05.019.

  40. Chan K.E., Edelman E.R., Wenger J.B. et al. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015; 131(11): 972–79. doi: 10.1161/CIRCULATIONAHA.114.014113.

  41. Jain N., Reilly R.F. Clinical pharmacology of oral anticoagulants in patients with kidney disease. Clin J Am Soc Nephrol. 2018 May 25. pii: CJN.02170218. doi: 10.2215/CJN.02170218.

  42. Di Lullo L., Ronco C., Cozzolino M. et al. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation. Thromb Res. 2017; 155: 38–47. doi: 10.1016/j.thromres.2017.04.027.

  43. Heo Y.A. Andexanet alfa: first global approval. Drugs. 2018; 78(10): 1049–55. doi: 10.1007/s40265-018-0940-4.

  44. Jun M., James M.T., Manns B.J. et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015; 350: h246. doi: 10.1136/bmj.h246.

  45. Nigwekar S.U., Kroshinsky D., Nazarian R.M. et al. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015; 66(1): 133–46. doi:10.1053/j.ajkd.2015.01.034.

  46. Di Lullo L., Tripepi G., Ronco C. et al. Cardiac valve calcification and use of anticoagulants: preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2019; 278: 243–49. doi: 10.1016/j.ijcard.2018.11.119.

  47. Задионченко В.С., Шехян Г.Г., Щикота А.М. с соавт. Место Варфарина в лечении и профилактике тромбоэмболий. РМЖ. 2011; 26: 1648–57.

  48. Qamar A., Bhatt D.L. Stroke prevention in atrial fibrillation in patients with chronic kidney disease. Circulation. 2016; 133(15): 1512–15. doi: 10.1161/CIRCULATIONAHA.115.018549.

  49. Fazio G., Dentamaro I., Gambacurta R. et al. Safety of edoxaban 30mg in elderly patients with severe renal impairment. Clin Drug Investig. 2018; 38(11): 1023–30. doi: 10.1007/s40261-018-0693-6.

  50. Stanton B.E., Barasch N.S., Tellor K.B. Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017; 37(4): 412–19. doi: 10.1002/phar.1905. Epub 2017 Mar 10.

  51. Bansal V.K., Herzog C.A., Sarnak M.J. et al. Oral anticoagulants to prevent stroke in nonvalvular atrial fibrillation in patients with CKD stage 5D: an NKF-KDOQI controversies report. Am J Kidney Dis. 2017; 70(6): 859–68. doi: 10.1053/j.ajkd.2017.08.003.

  52. Mueck W., Lensing A., Agnelli G. et al. Population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011; 50(10): 675–86. doi: 10.2165/11595320-000000000-00000.

  53. January C.T, Wann L.S., Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ ACC/HRS guideline for the management of patients with atrial fibrillation. Circulation. 2019; 140: e125–e151.doi:10.1161/CIR.0000000000000665.

  54. Khadzhynov D., Wagner F., Formella S. et al. Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with endstage renal disease. Thromb Haemost. 2013; 109(4): 596–605. doi: 10.1160/TH12-08-0573.

  55. Мухин Н.А., Глыбочко П.В., Свистунов А.А. с соавт. Хроническая болезнь почек и фибрилляция предсердий как компоненты кардиоренального континуума. Терапевтический архив. 2016; 88(6): 4–8. [Mukhin N.A., Glybochko P.V., Svistunov A.A. et al. Chronic kidney disease and atrial fibrillation as components of the cardiorenal continuum. Terapevticheskiy arkhiv. 2016; 88(6): 4–8 (In Russ.)]. doi: 10.17116/terarkh20168864-8.

  56. Baber U., Howard V.J., Halperin J.L. et al. Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Circ Arrhythm Electrophysiol. 2011; 4(1): 26–32. doi: 10.1161/CIRCEP.110.957100.

  57. Soliman E.Z., Prineas R.J., Go A.S. et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J. 2010; 159(6): 1102–07. doi: 10.1016/j.ahj.2010.03.027.

  58. Limdi N.A., Beasley T.M., Baird M.F. et al. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009; 20(4): 912–21. doi: 10.1681/ASN.2008070802.

  59. Лукьянов М.М., Бойцов С.А., Якушин C.С. с соавт. Диагностика, лечение, сочетанная сердечно-сосудистая патология и сопутствующие заболевания у больных с диагнозом «фибрилляция предсердий» в условиях реальной амбулаторно-поликлинической практики (по данным Регистра КардиоВАскулярных ЗАболеваний РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2014; 10(4): 366–377. [Loukianov M.M., Boytsov S.A., Yakushin S.S. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of «atrial fibrillation» in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Ratsional'naya farmakoterapiya v kardiologii. 2014; 10(4): 366–377 (In Russ.)].

  60. Koos R., Krueger T., Westenfeld R. et al. Relation of circulating matrix Gla-protein and anticoagulation status in patients with aortic valve calcification. Thromb Haemost. 2009; 101: 706–13. doi: 10.1160/TH08-09-0611.

  61. Кобалава Ж.Д., Шаваров А.А. Нюансы антикоагулянтной терапии у пациентов с хронической болезнью почек и фибрилляцией предсердий. Кардиология. 2018; 58(10): 59–70. [Kobalava Zh.D., Shavarov A.A. Nuances in anticoagulation treatment in patients with chronic kidney disease and atrial fibrillation. Kardiologiya. 2018; 58(10): 59–70 (In Russ.)]. doi: 10.18087/cardio.2018.10.10185.


About the Autors

Natalia G. Poteshkina, MD, professor, head of the Department of general therapy, faculty of additional professional education of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, therapist, consultant of Clinical city hospital No. 52 of Moscow Healthcare Department. Address: 123182, Moscow, 3 Pekhotnaya Str. Tel.: +7 (910) 442-22-16. E-mail: natpa@yandex.ru
Natalya S. Krylova, PhD, associate professor of the Department of general therapy, faculty of additional professional education of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, doctor of functional diagnostics of Clinical city hospital No. 52 of Moscow Healthcare Department. Address: 123182, Moscow, 3 Pekhotnaya Str. Tel.: +7 (903) 660-31-68. E-mail: krylova_n@list.ru
Ludmila V. Miheeva, resident of the Department of general therapy, faculty of additional professional education of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 123182, Moscow, 3 Pekhotnaya Str. Tel.: +7 (905) 525-44-62. E-mail: mikheeval94@mail.ru
Alla B. Khadzegova, MD, professor of the Department of general therapy, faculty of additional professional education of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 123182, Moscow, 3 Pekhotnaya Str. (Clinical city hospital No. 52 of Moscow Healthcare Department). Tel.: +7 (499) 196-19-69. E-mail: alla.h@mail.ru


Similar Articles

Back to Content

Бионика Медиа